The dismal outcome of stage IIIB colon cancer highlights the need for targeted therapies on the basis of effective predictive biomarkers, such as microRNA (miRNA).
Microarray was used to compare the miRNA expression profiles for 8 stage III B colon cancer patients with worse prognosis (metastases between 8 months and 18 months) and 8 cured stage III B colon cancer patients. Quantitative real-time polymerase chain reaction (qRT-PCR) analysis of the expression of targeted miRNAs was performed on tumor tissue of 98 patients with stage IIIB B colon cancer. A predictive model for 5-year disease-free survival (DFS) and overall survival (OS) was constructed using Kaplan–Meier analysis, logistic and Cox regression.
miRNA-192-3p and miRNA-192-5p were down regulated in group with worse prognosis (P = 0.026 and P = 0.042 respectively). Patients with higher expression of miRNA-192-5p had higher 5-year DFS (84.21%) and OS (89.47%) than those with lower targeted miRNA expression (DFS 38.8%, HR: 3.74, 95% confidence interval (CI): 1.52-9.23, P: 0.04; OS 48.57%, HR: 5.01, 95%CI: 1.75-14.38, P: 0.03). Patients with higher expression MiRNA-192-3p did not statistically impact the survival in this setting (DFS 73.33%vs64.7%, HR:0.68, 95%CI: 0.31-1.52, P:0.35; OS 76.67%vs66.17%, HR: 0.62, 95% CI: 0.27-1.45, P: 0.27).
MiRNA-192-5p is highly predictive marker for stage III B colon cancer patients. MiRNA-192-3p had no predictive value in this setting
Clinical trial identification
Legal entity responsible for the study
P. Li, Q. Ou, G. Chen, F.S. Oduncu
Sun Yat-sen University
All authors have declared no conflicts of interest.